/
Oncology
B-Cell Malignancies
40
Pipeline Programs↗
40
Active Trials↗
48
Companies Involved↗
B-cell Malignancies is a moderately active landscape with 40 programs across 48 companies. The most active players are Cellectar Biosciences, Inc., Regeneron, Fate Therapeutics. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 129
Phase 27
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
28 of 34 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 100% of 40 pipeline programs.
Analysis
Trial Status
115
clinical trials
Unknown status29 · 25%
Completed25 · 22%
Recruiting20 · 17%
Terminated17 · 15%
Active, not recruiting11 · 10%
Not yet recruiting9 · 8%
Other4 · 3%
Clinical Trials
Trial Activity
115 trials
JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies
Recruiting·—·N/A·NCT07065279·36 enrolled
Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies
Recruiting·—·N/A·NCT07345728·28 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)